No Data
No Data
MoonLake Immunotherapeutics: A Strong Buy on Robust Clinical Program and Financial Health
Barclays Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherap Is Maintained at Buy by Needham
Express News | Needham Maintains Buy on MoonLake, Lowers Price Target to $62
These Stock Picks Were No Ticket to Paradise -- Heard on the Street
Express News | MoonLake Immunotherapeutics : Needham Cuts Target Price to $62 From $66
No Data